Revenue and Profitability - Revenue for Q2 2024 was 140thousand,adecreaseof12197 thousand, compared to 174thousandinthesameperiodof2023,withagrossmarginof422.7 million for the first half of 2024, which is 1.5millionlowerthanthenetlossof4.2 million in the same period of 2023 [7]. Operating Expenses - Total operating expenses for the first half of 2024 were 2.9million,areductionof1.5 million compared to 4.4millioninthefirsthalfof2023[7].ProductDevelopmentandLaunches−TiviclaunchedClearUP2.0,whichincludesnewpowermanagementcircuitryforfasterchargingandlongerbatterylife,addressingpreviouscustomercomplaints[4].−Tivic′sPhase1trialofnon−invasivevagusnervestimulation(VNS)showedpromisingresults,indicatingpotentialclinicalutilityinmajordiseaseareas[2].StrategicPartnershipsandAgreements−Thecompanyenteredalimitedexclusivedistributionagreementwithatop10medicalequipmentdistributorintheU.S.[4].FinancialPositionandFutureOutlook−Thecompanyraisedapproximately4.0 million through a public offering of 4,710,000 shares at a price of 0.85pershare[7].−CashandcashequivalentsasofJune30,2024,totaled3.7 million, an increase from $3.4 million at the end of 2023 [7]. - The company expects future growth to be significantly enhanced by advancements in its vagus nerve stimulation program [3].